Marinus Pharmaceuticals, Inc. (MRNS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

1.4300

-0.1400

(-8.92%)

At close: 04:00PM EDT

1.4999

+0.07

(+4.89%)

After hours:

07:20PM EDT

Loading interactive chart...

Zacks
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Lags Revenue Estimates
Marinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 0% and 10.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
RADNOR, Pa., May 08, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024.
Zacks
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.